These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 30149986)

  • 1. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
    Tsuchihashi K; Ito M; Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Satake H; Suto T; Sugimoto N; Katsumata K; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Okuyama H; Sakai D; Ueno H; Tamura T; Yamashita K; Kishimoto J; Shimada Y; Baba E
    Clin Colorectal Cancer; 2018 Dec; 17(4):e687-e697. PubMed ID: 30149986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
    Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
    Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study.
    Nakashima M; Takeuchi M; Kawakami K
    Clin Colorectal Cancer; 2020 Dec; 19(4):e208-e225. PubMed ID: 32912821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
    Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y
    Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis.
    Nakashima M; Takeuchi M; Tanaka S; Kawakami K
    Anticancer Res; 2021 Feb; 41(2):1055-1062. PubMed ID: 33517315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
    Masuishi T; Taniguchi H; Hamauchi S; Komori A; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
    Clin Colorectal Cancer; 2017 Jun; 16(2):e15-e22. PubMed ID: 27670892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
    Sonbol MB; Benkhadra R; Wang Z; Firwana B; Walden DJ; Mody K; Hubbard JM; Murad MH; Ahn DH; Bekaii-Saab T
    Oncologist; 2019 Sep; 24(9):1174-1179. PubMed ID: 31164455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
    Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
    Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer.
    Matsuhashi N; Takahashi T; Fujii H; Suetsugu T; Fukada M; Iwata Y; Tokumaru Y; Imai T; Mori R; Tanahashi T; Matsui S; Imai H; Tanaka Y; Yamaguchi K; Futamura M; Yoshida K
    Mol Clin Oncol; 2019 Oct; 11(4):390-396. PubMed ID: 31475067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
    Boukovala M; Modest DP; Ricard I; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Uhlig J; Schenk M; Freiberg-Richter J; Peuser B; Denzlinger C; Peveling Genannt Reddemann C; Graeven U; Schuch G; Schwaner I; Heinrich K; Neumann J; Jung A; Held S; Stintzing S; Heinemann V; Michl M
    ESMO Open; 2024 May; 9(5):103374. PubMed ID: 38744100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
    Ergun Y; Bal O; Dogan M; Uncu D
    J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
    Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
    Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
    Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
    Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
    Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
    Cho SK; Hay JW; Barzi A
    Clin Colorectal Cancer; 2018 Dec; 17(4):e751-e761. PubMed ID: 30228027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
    Sueda T; Sakai D; Kudo T; Sugiura T; Takahashi H; Haraguchi N; Nishimura J; Hata T; Hayashi T; Mizushima T; Doki Y; Mori M; Satoh T
    Anticancer Res; 2016 Aug; 36(8):4299-306. PubMed ID: 27466548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States.
    Nevala-Plagemann C; Sama S; Ying J; Shen J; Haaland B; Florou V; Garrido-Laguna I
    J Natl Compr Canc Netw; 2023 Feb; 21(3):257-264. PubMed ID: 36812939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
    Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
    Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.